Scarica l'app Stockscreener
2.77
2.81%
-0.08
Indaptus Therapeutics Inc Borsa (INDP) Ultime notizie
Indaptus Therapeutics Company Profile & Introduction - Moomoo
Indaptus Therapeutics (INDP) News Flow - Moomoo
Form 13D/A Indaptus Therapeutics For: 26 June By Investing.com - Investing.com Australia
Sino Lion Ventures (INDP) files amended 13D on 38,895,000 shares - Stock Titan
Indaptus Therapeutics (INDP) CEO details 8.44% common stock stake - Stock Titan
Indaptus (INDP) investor Ting Yang stake falls to 8.44% after share issuance - Stock Titan
Form S-3 Indaptus Therapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Indaptus Therapeutics (INDP) registers 18.864M shares; clinical program paused - Stock Titan
Yun Yao (NASDAQ: INDP) reports 31.5% Indaptus stake change - Stock Titan
Revenue per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP - TradingView
INDAPTUS THERAPEUTICSTO ISSUE 20 MLN SHARES AT $0.6 PER SHARESEC FILING - Moomoo
Indaptus TherapeuticsTo Issue 20 Million Shares At $0.6 Per ShareSEC Filing - TradingView
Indaptus Therapeutics Announces Private Placement of Common Stock - TipRanks
Indaptus Therapeutics (INDP) sells 20M shares in $12M Regulation S private placement - Stock Titan
Indaptus Therapeutics Raises $12 Million in Offshore Private Placement at $0.60 Per Share - TradingView
Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form PRE 14A Sunshine Biopharma Inc For: 22 June By Investing.com - Investing.com Australia
Indaptus Therapeutics (INDP) asks shareholders to approve $300M PIPE, equity plan - Stock Titan
Indaptus Therapeutics Inc (INDP) Institutional Confidence - TradingKey
Indaptus Therapeutics Inc (INDP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Indaptus Therapeutics Inc (INDP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Indaptus Therapeutics Inc (INDP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Top Cue Biopharma (CUE) Competitors 2026 - MarketBeat
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders - Caledonian Record
Indaptus Therapeutics, Inc. announced that it expects to receive $12 million in funding - marketscreener.com
INDP Q4 2025 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentNet Income Trends - newsline.com
12 Health Care Stocks Moving In Thursday's Intraday SessionAdial Pharmaceuticals (NASDAQ:ADIL), Aditxt - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
INDP Q4 2025 Earnings: EPS Misses Estimates, Stock Tumbles 42.62%Quarterly Earnings Report - newsline.com
Indaptus Therapeutics (INDP) Plunges 42% as Selling Pressure IntensifiesUp Down Volume - newsline.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Indaptus Therapeutics, Inc. Files Form 8-K Announcing CEO Change – Junyi Dai Appointed CEO - Minichart
Indaptus Therapeutics Announces Recent Board and Leadership Changes - TipRanks
Indaptus Therapeutics directors David E. Lazar and Avraham Ben-Tzvi resign; Walt A. Linscott steps down as COO - TradingView
Leadership shifts at Indaptus Therapeutics (NASDAQ: INDP) as directors and COO exit - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Indaptus Therapeutics (INDP) Jumps 53.8% Amid Heavy Volume as Investors Focus on Financing/strategic-option Uncertainty - Moomoo
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative
INDPIndaptus Therapeutics Inc Forecast, Target Price - Finviz
INDP Q4 2025 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Focuses on Pipeline MilestonesMargin Expansion Trends - newsline.com
Indaptus Therapeutics Drops on Cash Runway Worries - Bez Kabli
Indaptus Therapeutics Inc. (INDP) Plunges 9.8% as Shares Approach Key Support ZoneGap Down Bounce Plays - Newser
INDP Q4 2025 Earnings: EPS Misses Estimates as Pre-Clinical Costs Continue, Stock Declines 9%Revenue Growth Outlook - newsline.com
Indaptus Therapeutics Q4 2025 Earnings: EPS Misses Estimates on Minimal Revenue, Stock SurgesFree Cash Flow Trends - The Legal Advocate
Indaptus Therapeutics Inc. (INDP) Q4 2025 Earnings: Deeper Loss, Yet Shares Surge on Pipeline ProgressRevenue Warning Signal - Newser
Indaptus Therapeutics (INDP) Surges 15%: Biotech Stock Breaks Above Key ResistanceMarket Hype Signals - Newser
Earnings Scheduled For May 15, 2026 - Sahm
Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing - Minichart
1.67%
3.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):